<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00411541</url>
  </required_header>
  <id_info>
    <org_study_id>I-BFM-SG IR ALL</org_study_id>
    <nct_id>NCT00411541</nct_id>
  </id_info>
  <brief_title>Pulses of Vincristine and Dexamethasone in BFM Protocols for Children With Acute Lymphoblastic Leukemia</brief_title>
  <official_title>Pulses of Vincristine and Dexamethasone During Maintenance in BFM Protocols for Children With Intermediate-Risk Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International BFM Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Associazione Italiana Ematologia Oncologia Pediatrica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>BFM-A, Austria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>BFM-G, Germany and Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CPH, Czech republic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GATLA, Argentina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>H-POG, Hungary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PINDA, Chile</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>International BFM Study Group</source>
  <brief_summary>
    <textblock>
      Studies in the 1970s and 1980s suggested that the outcome of childhood acute lymphoblastic
      leukemia could be improved by intensification of conventional continuation chemotherapy with
      pulses of vincristine sulfate and steroids. We aimed to investigate the efficacy and toxic
      effects of vincristine-dexamethasone pulses as an addition to the continuation-therapy phase
      in a large cohort of children with intermediate-risk disease who were treated with the BFM
      treatment strategy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study enrols children from 8 participating organizations. All children are treated with
      similar protocols based on the BFM treatment strategy, which include induction,
      consolidation, reinduction and continuation-therapy phases. At the beginning of the
      continuation-therapy phase, those patients in complete remission are randomly assigned to
      either a treatment or a control group. Control patients are given conventional mercaptopurine
      and methotrexate chemotherapy only. Patients in the treatment arm are also given pulses of
      vincristine (1.5 mg/sqm weekly for 2 weeks) and dexamethasone (6 mg/sqm daily for 7 days)
      every 10 weeks for six cycles.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 1995</start_date>
  <completion_date>January 2004</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>survival</measure>
  </secondary_outcome>
  <enrollment>2600</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &lt;1 or &gt;5 years or

          -  white blood cell count at diagnosis &gt;=20000

        Exclusion Criteria:

          -  prednisone poor response

          -  no complete remission at the end of induction (IA)

          -  t(9,22) clonal translocation

          -  t(4,11) clonal translocation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Schrappe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>BFM-G, Germany and Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helmut Gadner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>BFM-A, Austria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giuseppe Masera, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AIEOP, Itlay</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan Stary, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CPH, Czech republic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ives Benoit, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>EORTC-CLG, France, Belgium, Portugal</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edina Magyarosy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>H-POG, Hungary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Myriam Campbell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PINDA, Chile</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eduardo Dibar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GATLA, Argentina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Pediatric Hematology-Oncology, Italian Hospital</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Cancer Research Institute, St Anna Kinderspital</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pediatric Hemato-Oncology, Gent University Hospital</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pediatrics Hematology and Oncology, Hospital Roberto del Rio</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pediatric Hematology and Oncology, University Hospital Motol</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pediatrics, Semmelweis University</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Clinic - University of Milano-Bicocca</name>
      <address>
        <city>Monza</city>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Chile</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2006</study_first_submitted>
  <study_first_submitted_qc>December 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2006</study_first_posted>
  <last_update_submitted>December 13, 2006</last_update_submitted>
  <last_update_submitted_qc>December 13, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2006</last_update_posted>
  <keyword>acute lymphoblastic leukemia, maintenance, BFM protocol</keyword>
  <keyword>intermediate risk childhood acute lymphoblastic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

